NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.06. The biotechnology company earned $69.16 million during the quarter, compared to the consensus estimate of $78.65 million. Ironwood Pharmaceuticals had a negative net margin of 34.12% and a negative return on equity of 2,073.20%. The firm's quarterly revenue was up 32.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

9 equities research analysts have issued twelve-month price objectives for Ironwood Pharmaceuticals' shares. Their predictions range from $13.00 to $25.00. On average, they expect Ironwood Pharmaceuticals' share price to reach $19.4444 in the next twelve months. View Analyst Ratings for Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totalling 18,814,070 shares, a decline of 12.2% from the April 30th total of 21,438,253 shares. Based on an average daily trading volume, of 1,695,797 shares, the short-interest ratio is currently 11.1 days. Approximately 13.7% of the shares of the company are sold short.

Some companies that are related to Ironwood Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals Intl (VRX), BeiGene (BGNE), Genmab A/S (GNMSF), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO) and Loxo Oncology (LOXO).

News coverage about IRWD stock has been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a news impact score of 0.10 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Ironwood Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (3.65%), OppenheimerFunds Inc. (1.70%), Northern Trust Corp (1.03%), Loomis Sayles & Co. L P (1.01%), Sector Gamma AS (0.74%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Artal Group S.A., State of Wisconsin Investment Board, Barclays PLC, Sector Gamma AS, Loomis Sayles & Co. L P, California Public Employees Retirement System and Russell Investments Group Ltd.. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie and Peter M Hecht. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, OppenheimerFunds Inc., UBS Group AG, Engineers Gate Manager LP, Point72 Asset Management L.P., Trexquant Investment LP, Schwab Charles Investment Management Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $18.44.

Ironwood Pharmaceuticals has a market capitalization of $2.80 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]